ライフサイエンスコーパス: cell surface marker

1 ell neoplasm that often expresses the CD4+ T cell surface marker.

2 cells has been difficult without a defining cell surface marker.

3 major glycoprotein 2 (GP2) as a PP-specific cell surface marker.

4 nto Th17 cells in vitro and in vivo via CD25 cell surface marker.

5 re limited by the lack of available specific cell surface markers.

6 e ISCs from mouse and human tissues based on cell surface markers.

7 al nerve, and immunofluorescence staining of cell surface markers.

8 4, KDR) and osteoblastic (osteocalcin [OCN]) cell surface markers.

9 her coagulation, inflammatory, or lymphocyte cell surface markers.

10 subpopulation characterized previously using cell surface markers.

11 arly-outgrowth colony-forming unit assay and cell surface markers.

12 ke cysts that selectively incorporate apical cell surface markers.

13 eased up-regulation of activation-associated cell surface markers.

14 xpression of both DC and monocyte/macrophage cell surface markers.

15 iling cytokines, intracellular molecules and cell surface markers.

16 st cells as shown by cellular morphology and cell surface markers.

17 an be identified by the presence of specific cell surface markers.

18 et been achieved due to the lack of specific cell surface markers.

19 ls that previously identified based on other cell surface markers.

20 y Ab responses due to an absence of specific cell surface markers.

21 using flow cytometry to determine lymphocyte cell surface markers.

22 protein assays for cytokine, chemokine, and cell surface markers.

23 as electrical activity, gene expression, and cell surface markers.

24 TNF-alpha(+)CD4(+) T cells expressing naive cell surface markers.

25 positive cells and increased stem/progenitor cell surface markers.

26 lliliter of blood and the fold expression of cell surface markers.

27 human fetal pancreatic differentiation using cell surface markers.

28 ytometry together with various hematopoietic cell surface markers.

29 he result of context-dependent expression of cell surface markers.

30 ined challenging due to the lack of specific cell surface markers.

31 oskeleton regulators and the localization of cell surface markers.

32 pol mRNA, intracellular p24 Gag protein, and cell surface markers.

33 ypically purified from the bone marrow using cell surface markers.

34 Fab:Fab interactions in targeting oligomeric cell-surface markers.

35 ession profiles and identification of unique cell-surface markers.

36 lacked mature arterial, venal, and lymphatic cell-surface markers.

37 mass cytometry revealed expression of unique cell-surface markers.

38 roid progenitor cells that express analogous cell-surface markers.

39 expression of APC (macrophages and dendritic cells) surface markers.

40 ngle-cell mass cytometric measurements of 14 cell surface markers, 20 signaling/cell cycle proteins,

41 unbiased manner a panel of all commonly used cell surface markers (280 genes) from individual cells.

42 ogenase-bright cells expressed CD34 or CD133 cell surface markers (57.0% and 27.1%, respectively), co

43 We show herein that the cell surface marker 6-sulfo LacNAc (slan) can define sla

44 for viral haemagglutinin (HA) expression and cell surface markers 8-16 hours post infection.

45 From the panel of 21 cell surface markers, 9 were overexpressed in fetal prog

46 nfection of DC with live 35000HP caused less cell surface marker activation than infection with heat-

47 also expressed higher levels of more mature cell surface markers, additionally linking inflammasome

48 ses were assessed by measuring expression of cell surface markers (adhesion molecules, fibrinogen-lik

49 Additional cytokines, cell surface markers, adhesion molecules, and accessory

50 ated with respect to endocytosis properties, cell surface markers, allostimulatory activity, and cyto

51 These cell surface markers allowed direct isolation of rare ce

52 ice, csGRP78 co-localized with the mesangial cell surface marker alpha8-integrin.

53 ary, we identified GD2 as a new CSC-specific cell surface marker and GD3S as a potential therapeutic

54 In summary, we describe here a novel cell surface marker and targeting tools for tumor macrop

55 thelial cells expressed specific endothelial cell surface markers and also exhibited the capacity for

56 bpopulations of CSCs, characterized by their cell surface markers and colony morphology, which can se

57 stem cells to reveal the connection between cell surface markers and distinct cell phenotypes.

58 We used a combination of flow cytometry for cell surface markers and enzyme-linked immunospot method

59 to different sub-populations on the basis of cell surface markers and examine their function in an in

60 comprised of distinct subsets with different cell surface markers and functional characteristics and

61 ntional dendritic cells (cDCs) with distinct cell surface markers and functions exist in mouse and hu

62 ancer cell line, which we first confirmed by cell surface markers and gene profiling to be highly enr

63 otypes, express telomerase activity, express cell surface markers and genes that characterize human E

64 Analysis of cell surface markers and immunoglobulin H gene rearrange

65 s include (1) the identification of distinct cell surface markers and other cellular properties in he

66 stinct subsets can be distinguished based on cell surface markers and pathophysiological function.

67 Changes in cell surface markers and patterns of gene expression are

68 d expression of CD80, CD86, CD40, and MHC-II cell surface markers and production of proinflammatory c

69 single skeletal stem cell population through cell surface markers and the development of single-cell

70 functional phenotypes characterized by their cell surface markers and their cytokine profiles.

71 this likeness extended into the non-ISCT MSC cell surface markers and trilineage differentiation, whi

72 ubsets based on their expression of specific cell surface markers and used them in our adoptive trans

73 s and healthy control donors share a similar cell-surface marker and gene expression profile.

74 l death (AICD) and expressed a unique set of cell-surface markers and gene profiles.

75 display significantly altered expression of cell-surface markers and produce increased inflammatory

76 ly, neutrophil morphology (nucleus shape and cell-surface markers) and functions (phagocytosis, degra

77 nology for measuring cell entity, evaluating cell surface marker, and peculiarly in the field of stem

78 xpress characteristic transcription factors, cell surface markers, and cytokines, including glycoprot

79 ion of apoptosis, acquisition of tumorigenic cell surface markers, and epithelial-mesenchymal transit

80 including those encoding effector cytokines, cell surface markers, and key transcription factors.

81 ptor (uPAR), a uniquely overexpressed cancer cell-surface marker, and facilitating the immune-mediate

82 Because many cell surface markers are shared between AML blasts and h

83 Tumor cell-surface markers are usually overexpressed or mutate

84 wed AME downregulates the expression of such cell surface markers as CD80, CD86, and major histocompa

85 interferon-gamma production, without losing cell surface markers associated with memory.

86 al cells in part by increasing the levels of cell surface markers associated with mesenchymal stem ce

87 We identified cell surface markers associated with repression of p16(I

88 effector T cells, and caused an increase in cell surface markers associated with T(Regs) such as Fox

89 nsplants in regenerative medicine depends on cell-surface marker-based characterization and/or purifi

90 eration of reagents that specifically target cell-surface markers, because transmembrane proteins are

91 n NMR biosensor that can identify a specific cell surface marker by targeted (129)Xe MRI.

92 and FACS analyses demonstrate that specific cell surface markers can be used to discriminate prostat

93 As the cell surface marker CD133 identifies cancer-initiating c

94 The cell surface marker CD133 is frequently used to identify

95 ed high Wnt activity was associated with the cell surface markers CD133, CD166, and CD29, but not CD2

96 Currently, the cell surface marker CD138 (SDC1) is used for this enrich

97 ive L3 for 48 h showed no alterations in the cell surface markers CD14, CD86, CD83, CD207, E-cadherin

98 ammatory T cells into tissues, or target the cell surface marker CD20 (rituximab; Rituxan for hematol

99 data in K562 leukemic cells, we identify the cell surface marker CD24 as co-varying with chromatin ac

100 A new study shows that a cell-surface marker, CD27, identifies the first point of

101 s with great thermogenic potential using the cell surface marker CD29.

102 (MLN), spleen and thymus were labeled for T cell surface markers (CD3, CD4, CD8) and intracellular F

103 The cell surface marker CD34 marks mouse hair follicle bulge

104 including CTNND1 and the early hematopoietic cell surface marker CD34, resulted in reduced leukemic g

105 Using cell surface markers (CD34, CD133, kinase insert domain

106 nterferon-gamma with a unique combination of cell surface markers (CD4(+)CD25(-)CD44(hi)CD62L(lo)) an

107 s of breast cancer stem cells (BCSCs) is the cell surface marker CD44.

108 d stem cell-like characteristics express the cell surface marker CD44.

109 a Matrigel-based differentiation assay, and cell surface markers CD44 and CD24.

110 ese pancreatic cancer stem cells express the cell surface markers CD44, CD24, and epithelial-specific

111 on of pancreatic cancer cells expressing the cell surface markers CD44, CD24, and epithelial-specific

112 stage transitions, marked by changes in the cell-surface markers CD44 and ICAM1, and a Nanog-enhance

113 Here, we explored this hypothesis by using 2 cell surface markers, CD44 and CD137, to isolate antitum

114 hat express IL-10, as well as Tr1-associated cell surface markers, CD49b and LAG-3, and transcription

115 rences between these profiles, we identified cell surface markers, CD69 and CD36, whose genes were di

116 )/CCR4(+) T cells that also lack the usual T cell surface markers CD7 and/or CD26.

117 seq data, we defined a novel set of possible cell surface markers (Cd74 and Cd81) for these candidate

118 -surface protein also known as the leukocyte cell-surface marker CD82.

119 n the low nanomolar range, we identified the cell surface marker CD86 as a sensitive surrogate biomar

120 ls based on a variety of phenotypes, such as cell surface markers, cell proliferation and drug respon

121 B in vitro, as measured by the expression of cell surface markers, cellular signaling events, and cyt

122 man MDDCs exposed to galectin-1 up-regulated cell surface markers characteristic of DC maturation (CD

123 ubsets of HPCs examined, including HPCs with cell surface markers consistent with immature hematopoie

124 ssion signatures, morphological changes, and cell surface markers consistent with myeloid maturation.

125 e cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found th

126 within the tumor preferentially express the cell surface markers CTLA-4 and OX40.

127 Given the limited repertoire of cell-surface markers currently available for neural prog

128 oadly characterized by the expression of the cell surface marker CXCR4.

129 blood frequencies of MAIT cells, defined by cell surface markers, decline during tuberculosis (TB) d

130 etailed study has been hampered by a lack of cell surface markers defining tumor-specific dysfunction

131 Forty cell-surface markers, distinguishing all major leukocyte

132 is approach is that the presence of specific cell surface markers does not directly reflect the trans

133 umor cell (CTC) detection strategies rely on cell surface marker EpCAM and intracellular cytokeratins

134 XCL9, CXCL10, CXCL12, CXCL13 and CXCL16) and cell surface marker expression (CD3, CD4 and CXCR3) in p

135 eripheral blood, cutaneous mTregs had unique cell surface marker expression and cytokine production.

136 Although not affecting cell surface marker expression and phagocytotic function

137 lar trilineage differentiation potential and cell surface marker expression as bone marrow hMSCs.

138 ted control iDCs to WT capsule did not alter cell surface marker expression but did elicit IL-8.

139 onal profiling, TCR repertoire analyses, and cell surface marker expression indicate that Dock2-defic

140 normal, displaying no obvious compromise in cell surface marker expression or antibody production ei

141 n in vivo, and except for CD138, plasmablast cell surface marker expression was unaffected.

142 tro proliferation responses, alloreactivity, cell surface marker expression, and antibody production.

143 T cells showed convergence in the pattern of cell surface marker expression, cytokine profiles, and g

144 n of MEK1/2 did not reduce CT-B induction of cell surface marker expression, it did attenuate CT-B-me

145 nd, when isolated from skeletal muscle using cell surface marker expression, these cells showed compa

146 ains the decrease in cytokine production and cell surface marker expression.

147 entiation for at least 25 d, as evidenced by cell surface marker expression.

148 isolation, cells were characterized through cell-surface marker expression and lineage-specific diff

149 and, regardless of methodology for harvest, cell-surface marker expression of CD73, CD90, CD105, and

150 We used cell-surface marker expression to purify from the satell

151 lectively increased polyploidization, mature cell-surface marker expression, and apoptosis of maligna

152 Cell surface markers' expression and chemotaxis were det

153 transmembrane glycoprotein, is an important cell surface marker for both stem cells and cancer stem

154 CCR6 was the best cell surface marker for IL-17A+ cells when compared with

155 Moreover, huEGFRt provides a cell surface marker for in vivo tracking of adoptively t

156 xpression of CD83 (previously described as a cell surface marker for mature dendritic cells) on CD4 T

157 We further identified a cell surface marker for prospective isolation of iNCs, w

158 MUC16 is a well-validated cell surface marker for serous adenocarcinomas of the ov

159 matic stem cells, and it is widely used as a cell surface marker for the isolation and characterizati

160 Our identification of new cell surface markers for enriching mammosphere-initiatin

161 Existing cell surface markers for GSC are developed from embryoni

162 Our analysis identified 24 new/potential cell surface markers for murine fetal hepatic stem cells

163 ss I molecules offers unique cancer-specific cell surface markers for the identification and targetin

164 We further identify CORIN as a cell-surface marker for isolating the TBX5+NKX2-5+ subpo

165 ceptor (MC1R), which has been evaluated as a cell-surface marker for melanoma.

166 timulation during cancer immunotherapy and a cell-surface marker for pancreatic cancer.

167 nd proteomic approaches to identify specific cell-surface markers for cardiac PW1(+) cells and found

168 In this study, we attempted to identify cell-surface markers for leukemia-initiating cells in FA

169 Cell-surface markers for prospective isolation of stem c

170 of commercial antibodies, we have identified cell-surface markers for the separation of pancreatic ce

171 cently, a simple phenotype for HSCs based on cell surface markers from the signaling lymphocyte activ

172 ood, we acquired an immunological profile of cell-surface markers from healthy control and untreated

173 ytosis activity, viability and expression of cell-surface markers, from tens of thousands of single i

174 ssessment, nitro-blue tetrazolium reduction, cell-surface markers, genome-wide patterns of gene expre

175 h all the hallmarks of stem cells, including cell surface markers, global gene expression profiles, a

176 ent, both targeting the erythrocyte-specific cell surface marker glycophorin A.

177 However, lack of known unique mesangial cell surface markers has hampered this process.

178 allowing detection of increasing numbers of cell surface markers, has challenged the traditional tec

179 r functional phenotype, because few specific cell surface markers have been identified.

180 rious combinations of antibodies directed to cell surface markers have been used to isolate human and

181 Several cell-surface markers have been reported to identify cand

182 the basis of the differential expression of cell-surface markers, here we identify a mesenchymal str

183 ific membrane antigen (PSMA), a prototypical cell surface marker highly overexpressed in prostate can

184 utrophils, fibroblasts, and lymphocytes; and cell surface markers, ie, F4/80, CD11b, CD11c, and Ly-6C

185 ify and purify anergic T cells by a distinct cell surface marker in an autoimmune disease and paves t

186 he up-regulation of macrophage/hematopoietic cell surface markers in a large proportion of NIH 3T3 ce

187 Novel cell surface markers in adult progenitor cells included

188 e due to the impaired expression of relevant cell surface markers in Eklf(-/-) erythroid cells.

189 o studied expression of the identified novel cell surface markers in fetal rat liver progenitor cells

190 In this work, we studied progenitor/oval cell surface markers in the liver of rats subjected to 2

191 Persistence of respective cell surface markers in vitro is confirmed both by flow

192 responses, alloreactivity, and expression of cell surface markers in vitro.

193 selection using an optimized combination of cell surface markers including CD30.

194 ells that exhibit differential expression of cell surface markers, including CD105 (or endoglin), Thy

195 ethod was reported, using the SLAM family of cell-surface markers, including CD150 (SlamF1), to offer

196 Although exhibiting cell surface markers indicative of activation, the IL-10

197 The transcriptional profile identified 2 cell-surface markers, ITGA6 and NGFR, which can be used

198 n inflammatory cell numbers and cytokine and cell-surface marker levels on monocytes and macrophages.

199 gland stem cells (MaSCs) using combinatorial cell surface markers (Lin(-)CD24(+)CD29(h)CD49f(h)) has

200 lation based on the expression profiles of 2 cell-surface markers LNGFR (CD271) and THY-1 (CD90).

201 re the identification of TIM3 as an AML stem cell surface marker more highly expressed on multiple sp

202 PSMA is a unique cell surface marker, negatively regulated by androgen an

203 We have isolated rare cells bearing the NK cell surface marker NK1.1, as well as the dendritic cell

204 rapidly upregulate the expression of the NK cell-surface marker NK1.1 in response to MSU crystals bu

205 ty in vitro but lacked expression of myeloid cell surface markers normally seen with MLL-CBP.

206 e attenuates acute loss of the developing OL cell surface marker O1 and the mature OL marker MBP (mye

207 ir expression of CD4, CD8, naive, and memory cell-surface markers, occupy distinct homeostatic compar

208 CD44 is commonly used as a cell surface marker of cancer stem-like cells in epithel

209 xpression of CD146, a hypoxia down-regulated cell surface marker of human BM-MSCs.

210 e DLL1(+) cluster, revealed it to be a novel cell surface marker of human epidermal stem cells.

211 cell cycle progression and can be used as a cell surface marker of myofibroblasts.

212 11 receptor alpha subunit (IL-11Ralpha) as a cell surface marker of tumor progression that correlates

213 ets showed that effector memory pathways and cell surface markers of activation and proliferation in

214 ukocytes (VLC), due to sharing functions and cell surface markers of both dendritic cells and endothe

215 protein resulted in increased expression of cell surface markers of DC maturation and an increase in

216 that a group of immature myeloid cells with cell surface markers of Gr-1(+) CD11b(+) are highly enri

217 ion, cytokine production, proliferation, and cell surface markers of immune cells between GA-treated

218 ry CD8 T cells from naive old mice expressed cell surface markers of memory in addition to receptors

219 MSCs) were established and characterized for cell surface markers of mesenchymal stem cell origin in

220 also known as CD143), a recently identified cell-surface marker of adult human hematopoietic stem ce

221 CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells

222 In addition, the loss of CD28 cell surface markers on CD8 + T cells, an indicator of T

223 The expression of lymphoid cell surface markers on PBMC and splenocytes of mice hom

224 S, and microglial activation was assessed by cell surface marker or phospho-MAPK immunofluorescence.

225 eomic or flow cytometric characterization of cell surface markers or adoptive transfer.

226 ls (CSCs) can be identified by expression of cell surface markers or enzymatic activity, but these me

227 intercellular adhesion, without knowledge of cell-surface markers or intracellular proteins.

228 Flow cytometry utilizing the cell surface markers p75 and HNK-1 was used to isolate l

229 haracteristics such as cell cycle status and cell surface marker phenotype, they respond to different

230 These results demonstrate that CD96 is a cell surface marker present on many AML-LSC and may serv

231 ese results demonstrate that IL-3Ralpha is a cell-surface marker present on FA-AML leukemia-initiatin

232 vity was confirmed by examining cytokine and cell surface marker production in bone-marrow-derived de

233 n cytokine-supplemented medium changed their cell surface marker profile and gene expression pattern

234 sms are cells characterized by a CD44+/CD24- cell surface marker profile.

235 over 24 h, as indicated by up-regulation of cell surface marker proteins CD40, CD80, and CD86.

236 OV-1 antigen, a6 integrin, and connexin 43), cell surface markers recently identified by us (CD44, CD

237 in rat tissue, they distinctively express a cell surface marker recognized by the SE-1 antibody.

238 ation; SP) in conjunction with canonical HSC cell-surface markers (Sca-1, c-Kit, and lineage markers)

239 When combined with high-throughput cell surface marker screening, this approach facilitates

240 This study identifies FolR1 as a new cell surface marker selectively expressed in mesDA proge

241 The antennal lobe neuropil expressed the cell surface marker semaphorin 1a.

242 Analysis of cell surface markers showed an age-dependent increase in

243 identical sets of T(EM)-associated genes and cell surface markers shown to be associated with latency

244 These MDSCs express a cell surface marker signature (CD11b(+) Gr-1(+) Ly6C(+))

245 n is reliant on the presence of well-defined cell surface markers specific for diverse progenitor pop

246 We identified novel cell surface markers specific for hepatic progenitor/ova

247 cells as demonstrated by expression of stem cell surface markers such as aldehyde dehydrogenase 1, s

248 m is complicated by the shared expression of cell surface markers such as CD11c.

249 Identification of cell surface markers sufficient to purify Treg cells exp

250 ed by a remarkable up-regulation of specific cell surface markers, suggesting that LPS stimulation le

251 n of MSC with both endothelial and pericytic cell surface markers suppresses the homing of cancer cel

252 olobus purpureas agglutinin (TPA) as a novel cell surface marker that allows for such delineation.

253 These data suggest that AA4.1 is a cell surface marker that can identify the earliest lymph

254 CD20 is a B cell surface marker that is expressed in various stages

255 eceptor superfamily member OX40 (CD134) is a cell surface marker that is highly specific for activate

256 We identified 33 transcripts encoding cell surface markers that are differentially expressed b

257 e and chemokine responses, and expression of cell surface markers that are related to T cell activati

258 nitive endoderm with the goal of identifying cell surface markers that can be used to track the devel

259 t LSC, one potential strategy is to identify cell surface markers that can distinguish LSC from norma

260 ssociated with subclonal mutations, and find cell surface markers that could be used to purify subclo

261 We sought to delineate cell surface markers that could distinguish NK cells tha

262 In monocytes, we identify host cell surface markers that enable enrichment of latent ce

263 acteristics, as well as the precise panel of cell surface markers that uniquely define this newly des

264 ha,and IL-2, and up-regulation of numerous T cell surface markers that would promote T-T Ag presentat

265 These results reveal a cell-surface marker that delineates functional activity

266 , zymosan, heat-killed or live bacteria, and cell-surface markers that coexpress with FR were identif

267 We identify cell-surface markers that delineate a series of stress e

268 ptor type I and II (CD121a/CD121b) as unique cell-surface markers that distinguish activated Tregs fr

269 lls have been hampered by a lack of suitable cell-surface markers that specifically enable their puri

270 cell subsets that display either CD4 or CD8 cell surface markers, the leukemic cell is exclusively o

271 ltiple defects in the expression of effector cell surface markers, the synthesis of cytokines, and in

272 Upon recognizing the targeted cell-surface marker, the APH enters the host cell via en

273 D(2) receptor, CRTH2, the best selective Th2-cell surface marker to date.

274 op an assay based on loss of expression of a cell surface marker to monitor epigenetic instability at

275 crophages, while alphaCD47 blocks CD47 tumor cell surface marker to promote phagocytosis.

276 ling core-2 O-glycosylation and identified a cell surface marker to quantify Notch signals in multipl

277 Further, we identified potential cell surface markers to allow for future identification

278 ins on fibroblast cells, which are potential cell surface markers to differentiate endothelial and fi

279 tential in part independent of commonly used cell surface markers to discriminate effector and memory

280 We have used specific cell surface markers to examine the association of NG2 c

281 nhanced green fluorescent protein (eGFP) and cell surface markers to FACS-isolate DeltaSox2-eGFP(+) G

282 is due, in part, to the difficulty of using cell surface markers to identify CD4(+)CD25(+) T reg cel

283 we combine H2B-GFP-based pulse-chasing with cell-surface markers to distinguish quiescent from proli

284 ave used flow cytometry and a defined set of cell-surface markers to identify and subsequently isolat

285 ly carried out by quantification of multiple cell surface markers, transcription factors and cytokine

286 Human trophoblast cell-surface marker (Trop-2) is a surface glycoprotein o

287 eries of heterogeneous subpopulations in its cell surface markers, tumorigenicity, invasion and metas

288 The cells lacked expression of cell surface markers typically expressed by germinal cen

289 ver based on the expression of CD4 and other cell surface markers uniquely expressed by pDCs.

290 They discovered a panel of cell surface markers useful for isolating living hair fo

291 Expression of cell surface markers was assessed by flow cytometry.

292 The specificity of progenitor/oval cell surface markers was confirmed by ISH and double IF

293 A cell-surface marker was identified by comparing the mRNA

294 Additional cell surface markers were also used to quantify differen

295 he differential expression patterns of these cell surface markers were dependent on Ly49H recognition

296 Cell surface markers were screened for their ability to

297 cently identified myeloid lineage restricted cell surface marker, which is overexpressed in over 90%

298 Cs and a germline seminoma that share a CD38 cell-surface marker, which collectively defines likely p

299 CX3CR1, a cell surface marker whose expression is associated with

300 r-, costimulation-, or activation-associated cell surface markers yet were associated with lower Ly6C